iCAD (ICAD)
Oppenheimer analyst Francois Brisebois assigned a Buy rating to iCAD today and set a price target of $28.00. The company’s shares closed last Wednesday at $17.73.
According to TipRanks.com, Brisebois is a 3-star analyst with an average return of 10.2% and a 45.2% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Diamedica Therapeutics, and Kala Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for iCAD with a $23.43 average price target, representing a 29.3% upside. In a report issued on April 22, Guggenheim also initiated coverage with a Buy rating on the stock with a $24.00 price target.
Markets
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Kala Pharmaceuticals (KALA – Research Report), with a price target of $49.00. The company’s shares closed last Wednesday at $7.63.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.8% and a 43.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and Lexicon Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kala Pharmaceuticals with a $26.00 average price target, representing a 270.4% upside. In a report issued on April 9, J.P. Morgan also maintained a Buy rating on the stock with a $17.00 price target.
Tracon Pharmaceuticals (NASDAQ:TCON), TCP Capital Corp (NASDAQ:TCPC) - Earnings Scheduled For February 25, 2021 benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
46
Data Bridge Market research presents the top quality and comprehensive Viral conjunctivitis research report which provides clear insights into market dynamics and prospects the whole market including global production, revenue forecast, value and volume. This Viral conjunctivitis report deeply study competitive scenario and evaluated the crucial vendors with regard to product stratification and business strategies. It analyzes the detailed insight with respect to industries and geographies. The detailed information of the existed industries is the first acquired by the dedicated team to provide exact and accurate data of the market.
Viral conjunctivitis market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Rising prevalence of eye related disorders worldwide and emerging markets are the factors responsible for the growth o